Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 21,531 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes, SGLT-2i and GLP-1RA Therapies, Diffusion of Responsibility, Prescribing Burden
Interventions
Intervention to address diffusion of responsibility, Intervention to address diffusion of responsibility + simplification of prescribing
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
1,580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions
Best Practice, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Radiation Therapy
Other · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
552
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 357 more
Conditions
Colorectal Cancer
Interventions
irinotecan, fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
430
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 261 more
Conditions
Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
Interventions
Alemtuzumab, Tacrolimus, Mycophenolate mofetil, Sirolimus
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Conditions
Focal Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more
Conditions
Pain, Chronic, Pain, Musculoskeletal, Anxiety
Interventions
dCBT
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Light-Chain Amyloidosis
Interventions
Ixazomib, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • Rochester, Minnesota + 2 more
Conditions
Neoplasms, Malignant Carcinoma
Interventions
Neratinib, Temsirolimus
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Results available

Engaging Patients to Promote Deprescribing

NCT04294901
Conditions
Medical Overuse, Inappropriate Prescribing, Deprescriptions
Interventions
Direct to patient medication brochure
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
5,946 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Leeds, Massachusetts + 1 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms

NCT02641912
Conditions
Xerostomia
Interventions
Biotene mouthwash, Mineral Water
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Arformoterol tartrate inhalation solution, Tiotropium
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Waterbury, Connecticut + 24 more
Completed Phase 3 Interventional Results available

Treatment for Endogenous Cushing's Syndrome

NCT01838551
Conditions
Endogenous Cushing's Syndrome
Interventions
Levoketoconazole
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Conditions
Alcohol Abuse, Alcohol Dependence, Unhealthy Alcohol Use, Risky Alcohol Consumption Amounts, Hazardous Alcohol Use
Interventions
Brief Personalized Feedback
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
4,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Constipation
Interventions
Tegaserod and Polyethylene Glycol 3350
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
52 participants
Timeline
2005
U.S. locations
14
States / cities
Oro Valley, Arizona • Phoenix, Arizona • Tucson, Arizona + 11 more
Conditions
Breast Cancer
Interventions
Gene Modified T Cells, Gene Modified T Cells and Interleukin 2
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Conditions
Heart Failure
Interventions
Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking
Drug · Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Lung Adenocarcinoma, Pancreatic Cancer, Head and Neck Cancer
Interventions
PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3, PY159 Single agent dose level 4, PY159 Single agent dose level 5, PY159 Single agent dose level 6, PY159 Single agent dose level 7, PY159/Pembrolizumab Combination dose level 1, PY159/Pembrolizumab Combination dose level 2, PY159/Pembrolizumab Combination dose level 3, PY159/Pembrolizumab Combination dose level 4, PY159 Single agent dose expansion cohort, PY159/Pembrolizumab Combination dose expansion cohort 1, PY159/Pembrolizumab Combination dose expansion cohort 2, PY159/Pembrolizumab Combination dose expansion cohort 3, PY159/Pembrolizumab Combination dose expansion cohort 4, PY159/Pembrolizumab Combination dose expansion cohort 5, PY159/Pembrolizumab Combination dose expansion cohort 6
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more
Conditions
Secondary Hyperoxaluria, Nephrolithiasis, Kidney Stones, Hyperoxaluria, Dietary Hyperoxaluria
Interventions
ALLN-177 low dose, ALLN-177 mid dose, ALLN-177 high dose, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Los Angeles, California • Daytona Beach, Florida • Jacksonville, Florida + 13 more
Conditions
Obsessive Compulsive Disorder, Body Dysmorphic Disorder, Tourette Syndrome, Trichotillomania, Panic Disorder, Social Phobia, Generalized Anxiety Disorder, Depression, Post-Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder, Eating Disorder, Specific Phobia, General Medical Condition
Interventions
Cognitive behavioral therapy (CBT)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Intravitreal Aflibercept Injection 2mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
115
States / cities
Birmingham (2 Locations), Alabama • Phoenix (2 Locations), Arizona • Tucson (2 Locations), Arizona + 112 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Service and Health During the Iraq and Afghanistan Era

NCT01987401
Conditions
Iraq and Afghanistan Era Veterans
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
1,242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Conditions
Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma
Interventions
everolimus, bevacizumab
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Conditions
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
Interventions
Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin, Oxaliplatin, Pembrolizumab, Veliparib
Drug · Radiation · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
645
States / cities
Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 449 more
Conditions
Osteoarthritis
Interventions
Modified Citrus Pectin, Placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts